Citations

Clear

45 citation(s) found for "Conners, AL".

Comment on “Radiation Doses and Risks in Breast Screening”
Conners, Amy Lynn , Fazzio, Robert T. , Hunt, Katie N. , O’Connor, Michael K. , Rhodes, Deborah J. , Shermis, Robin B. , Ellis, Richard , O'Connor, Michael K, Ellis, Richard, Hruska, Carrie B.

Mayo Clinic

Journal of Breast Imaging | September 14, 2020 | Volume: 2 | Issue: 6 | Pages: 519-520

10.1093/jbi/wbaa074 | PMID 38424854 Get It

Background Parenchymal Uptake on Molecular Breast Imaging and Breast Cancer Risk: A Cohort Study
Geske, Jennifer R. , Conners, Amy Lynn , Whaley, Dana H. , Rhodes, Deborah J. , O’Connor, Michael K. , Carter, Rickey E. , Vachon, Celine M. , O'Connor, Michael K, Carter, Rickey E , Geske, Jennifer , Hruska, Carrie B. , Scott, Christopher G. , Vachon, Celine M.

Mayo Clinic

American Journal of Roentgenology | July 29, 2020 | Volume: 216 | Issue: 5 | Pages: 1193-1204

10.2214/ajr.20.23854 | PMID 32755210 Get It

Ability of Intraoperative Pathologic Analysis of Ductal Carcinoma In Situ to Guide Selective Use of Sentinel Lymph Node Surgery
Murphy, Brittany L. , Gonzalez, Alexandra B., Keeney, Michael, Chen, Beiyun, Conners, Amy Lynn , Henrichsen, Tara L. , Harmsen, William S. , Degnim, Amy C. , Boughey, Judy C. , Hieken, Tina J. , Habermann, Elizabeth B. , Jakub, James W.

Mayo Clinic

The American Surgeon™ | June 17, 2020 | Volume: 84 | Issue: 4 | Pages: 537-542

10.1177/000313481808400427 Get It

For patients with ductal carcinoma in situ (DCIS), sentinel lymph node (SLN) surgery is generally reserved for patients at high risk of being upstaged to invasive disease. The use of frozen section (FS) pathologic analysis of the primary tumor may allow for selective surgical nodal staging within one procedure. We sought to define the reliability of FS for detection of upstaging. Eight hundred and twenty-seven patients were identified with DCIS on core needle biopsy that underwent 834 operations at our institution between January 2004 and October 2014. We calculated the rate of upstage from DCIS to invasive cancer on both intraoperative FS and final pathology to determine the performance of FS. Upstage rate on final pathology was 118/834 (14.1%) 95 per cent confidence interval 11.8 to 16.7 per cent. FS identified 88/118 (74.6%) of the upstages. Specificity was 99.3 per cent (711/716). Overall accuracy was 95.8 per cent (799/834) and the positive predictive value was 96.0 per cent (711/741 patients). Mean size of invasive cancers identifiedon FS was 5.6 mm, versus 3.5 mm for those identified only on permanent section, P = 0.11. Intraoperative FS analysis of DCIS is useful for identification of upstage to invasive disease. This may facilitate a selective approach to SLN surgery that both decreases unnecessary SLN surgery and the need for a second operation.
Molecular Breast Imaging in Patients with Suspicious Calcifications
Hunt, Katie N. , Johnson, Matthew P. , Conners, Amy Lynn , O’Connor, Michael K. , Rhodes, Deborah J. , Basappa, Susanna , Wahner‐Roedler, Dietlind L. , O'Connor, Michael K, Wahner-Roedler, Dietlind, Hruska, Carrie B.

Mayo Clinic

Journal of Breast Imaging | October 31, 2019 | Volume: 1 | Issue: 4 | Pages: 303-309

10.1093/jbi/wbz054 | PMID 38424809 Get It

AbstractObjectiveWe evaluated the accuracy of molecular breast imaging (MBI)—a nuclear medicine technique that employs dedicated dual-detector, cadmium zinc telluride gamma cameras to image the functional uptake of a radiopharmaceutical (typically Tc-99m sestamibi) in the breast—in patients with suspicious calcifications on mammography.MethodsWomen scheduled for stereotactic biopsy of calcifications detected on 2D digital mammography were prospectively enrolled to undergo MBI before biopsy. Molecular breast imaging was performed with injection of Tc-99m sestamibi and a dual-detector, cadmium zinc telluride gamma camera. Positive findings on either modality were biopsied. High-risk and malignant biopsy findings were excised.ResultsIn 71 participants, 76 areas of calcifications were recommended for biopsy after mammography, and 24 (32%) were malignant, including 20 cases of ductal carcinoma in situ (DCIS) and 4 cases of invasive ductal cancer. Prebiopsy MBI was positive in 17 of the 76 (22%) calcifications, including 10 of 20 (50%) DCISs and 2 of 4 (50%) invasive cancers. The median pathologic size for MBI–positive cancers was 1.5 cm (range 0.5–3.2 cm) compared with 0.9 cm (range 0.1–2.0 cm) for MBI–negative cancers (P = 0.09).Non-mass uptake on MBI led to additional biopsies of 6 sites in 6 patients, and 2 of 6 (33%) MBI–detected incidental lesions showed malignancy; both DCIS contralateral to the mammographically detected calcifications. The overall per-lesion positive and negative predictive values of MBI in this prebiopsy setting were 61% (14 of 23) and 80% (47 of 59), respectively.ConclusionMolecular breast imaging has insufficient negative predictive value to identify calcifications in which biopsy could be avoided. However, among women presenting for biopsy of suspicious calcifications, MBI revealed additional sites of mammographically occult breast cancer.To avoid biopsy of suspicious calcifications on mammography, negative findings on MBI should not be used.
Comparison of 99mTc-Sestamibi Molecular Breast Imaging and Breast MRI in Patients With Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy
Hunt, Katie N. , Conners, Amy Lynn , O’Connor, Michael K. , Weinshilboum, Richard, Wang, Liewei , Carter, Jodi M. , McLaughlin, Sarah A. , Aspitia, Alvaro Moreno, Gray, Richard J. , Northfelt, Don W., O'Connor, Michael K, Suman, Vera, Kalari, Krishna, Carter, Jodi, Northfelt, Don, Goetz, Matthew P. , Suman, Vera J. , Kalari, Krishna R. , Boughey, Judy C. , Carter, Jodi

Mayo Clinic

American Journal of Roentgenology | June 5, 2019 | Volume: 213 | Issue: 4 | Pages: 932-943

10.2214/ajr.18.20628 | PMID 31166752 Get It

Abstract PD4-05: Molecular breast imaging and tomosynthesis to eliminate the reservoir of undetected cancer in dense breasts: The Density MATTERS trial
Rhodes, Deborah J. , Hunt, Katie N. , Conners, Amy Lynn , Zingula, Shannon N. , Whaley, Dana H. , Rl, Ellis, Spilde, Jeannette Gasal, Mehta, Ramila A. , Polley, M-Y, O’Connor, Michael K. , Ellis, R, Hruska, Carrie B.

Mayo Clinic

Cancer Research | May 11, 2019 | Volume: 79 | Issue: 4_Supplement | Pages: PD4-05-PD4-05

10.1158/1538-7445.sabcs18-pd4-05 Get It

Abstract Background High mammographic breast density is the primary reason for missed cancers or delayed detection on mammography, and is associated with a higher rate of advanced and interval cancers which increase breast cancer mortality. Digital breast tomosynthesis (DBT) has been shown to reduce false positive findings relative to 2D mammography but does not eliminate the potential for tumor masking in dense breasts due to the similar x-ray attenuation characteristics of tumors and normal fibroglandular tissue. Molecular Breast Imaging (MBI) performed with a dedicated gamma camera to detect functional uptake of a radiotracer, Tc-99m sestamibi, has been shown to reveal breast cancers obscured by density on mammography. In single-institution studies, adding MBI to 2D mammography in women with dense breasts detected an additional 5 to10 invasive cancers per 1000 screened, with modest increases in recall rate (6 to 8%) at a lower cost-per-cancer detected than mammography alone. Despite this promising evidence, the lack of multicenter trial data has limited wider acceptance. Also, MBI has yet to be compared to DBT, which in some centers has replaced 2D mammography screening. We present interim results from a multicenter trial comparing cancer detection rate of DBT and MBI in screening of women with mammographically dense breasts. Methods In this ongoing, prospective, multicenter clinical trial, asymptomatic women aged 40-75 years with dense breasts on prior mammogram and no prior history of supplemental screening are invited to undergo two annual rounds of concurrent DBT and MBI. MBI is performed with injection of 300 MBq Tc-99m sestamibi with a dual-head semiconductor-based gamma camera. Screening tests are interpreted independently. Here, preliminary cancer detection rates (cancers per 1000 women screened), recall rates, and biopsy rates of DBT and MBI for initial screening are reported. Results In 537 women out of a planned 3000 who have completed the first round of screening, 7 cancers were detected: one by DBT only and 6 by MBI only, giving cancer detection rates of 1.9 for DBT vs. 11.2 for MBI and incremental cancer detection rate of 9.3 for MBI. The one DBT-only cancer was a node-negative 0.8 cm invasive lobular carcinoma. All 6 cancers detected by MBI were invasive; 5 of 6 were node negative (median size 1.0 cm; range 0.6 to 2.6 cm). Recall rate was 11% (60/537) for DBT alone; 16% (84/537) for MBI alone, and 21% (115/537) for the combination. Biopsy was prompted by DBT in 13 patients (PPV 8% [1/13]); by MBI in 23 patients (PPV 26% [6/23]); and by the combination of modalities in 33 (PPV 21% [7/33]). Conclusion These preliminary results demonstrate that MBI detects invasive breast cancers occult on DBT in dense breasts. Data from a second screening round will allow calculation of sensitivity and specificity, and determination of the impact of screening MBI in reducing advanced (> 2 cm) and interval cancers. Additional planned analyses will evaluate a denoising algorithm for further reduction in MBI radiation dose to match that of DBT. Citation Format: Rhodes D, Hunt K, Conners A, Zingula S, Whaley D, Ellis R, Gasal Spilde J, Mehta R, Polley M-Y, O'Connor M, Hruska C. Molecular breast imaging and tomosynthesis to eliminate the reservoir of undetected cancer in dense breasts: The Density MATTERS trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD4-05.
Classification of Background Parenchymal Uptake on Molecular Breast Imaging Using a Convolutional Neural Network
Carter, Rickey E. , Geske, Jennifer R. , Conners, Amy Lynn , Whaley, Dana H. , Hunt, Katie N. , O’Connor, Michael K. , Rhodes, Deborah J. , O'Connor, Michael K, Hruska, Carrie B. , Carter, Rickey E , Attia, Zachi I. , Geske, Jennifer

Mayo Clinic

JCO Clinical Cancer Informatics | February 26, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-11

10.1200/cci.18.00133 | PMID 30807208 Get It

PURPOSE Background parenchymal uptake (BPU), which describes the level of radiotracer uptake in normal fibroglandular tissue on molecular breast imaging (MBI), has been identified as a breast cancer risk factor. Our objective was to develop and validate a deep learning model using image convolution to automatically categorize BPU on MBI. METHODS MBI examinations obtained for clinical and research purposes from 2004 to 2015 were reviewed to classify the BPU pattern using a standardized five-category scale. Two expert radiologists provided interpretations that were used as the reference standard for modeling. The modeling consisted of training and validating a convolutional neural network to predict BPU. Model performance was summarized in data reserved to test the performance of the algorithm at the per-image and per-breast levels. RESULTS Training was performed on 24,639 images from 3,133 unique patients. The model performance on the withheld testing data (6,172 images; 786 patients) was evaluated. Using direct matching on the predicted classification resulted in an accuracy of 69.4% (95% CI, 67.4% to 71.3%), and if prediction within one category was considered, accuracy increased to 96.0% (95% CI, 95.2% to 96.7%). When considering the breast-level prediction of BPU, the accuracy remained strong, with 70.3% (95% CI, 68.0% to 72.6%) and 96.2% (95% CI, 95.3% to 97.2%) for the direct match and allowance for one category, respectively. CONCLUSION BPU provided a robust target for training a convolutional neural network. A validated computer algorithm will allow for objective, reproducible encoding of BPU to foster its integration into risk-stratification algorithms.
Patient-derived xenografts from breast cancer patients before and after neoadjuvant chemotherapy: A prospective study.
Yu, Jia , Gao, Bowen , Moyer, Ann M. , Visscher, Daniel W., Conners, Amy Lynn , Dockter, Travis , Jones, Katie N., McLaughlin, Sarah A. , Copland, John A. , Moreno‐Aspitia, Alvaro , Northfelt, Donald W. , Gray, Richard J. , Weinshilboum, Richard M. , Wang, Liewei , Boughey, Judy C. , Yin, Ping , Sinnwell, Jason P. , Kalari, Krishna R. , Suman, Vera J. , Weinshilboum, Richard M. , Goetz, Matthew P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 11130-11130

10.1200/jco.2014.32.15_suppl.11130 Get It

Masses in the era of screening tomosynthesis: Is diagnostic ultrasound sufficient?
Choudhery, Sadia, Axmacher, Jessica A, Conners, Amy Lynn , Geske, Jennifer R. , Brandt, Kathy R., Axmacher, Jessica, Geske, Jennifer, Brandt, Kathy, Geske, Jennifer

Mayo Clinic

The British Journal of Radiology | November 29, 2018 | Volume: 92 | Issue: 1096 | Pages: No page available

10.1259/bjr.20180801 | PMID 30495975 Get It

Objectives: The purpose of this study is to compare diagnostic outcomes of digital breast tomosynthesis screen-detected masses worked up with mammography first with those evaluated with diagnostic ultrasound initially. Methods: All masses recalled from screening digital breast tomosynthesis between July 1, 2017 and December 31, 2017 that were sent either to diagnostic mammography or ultrasound were compared. Size, shape, margins, visibility on ultrasound, diagnostic assessment and pathology of all masses along with breast density were evaluated. Results: 102/212 digital breast tomosynthesis screen-detected masses were worked up with diagnostic mammography initially and 110/212 were worked up with ultrasound directly. There was no significant difference in ultrasound visibility of masses sent to diagnostic mammography first with those sent to ultrasound first (p = 0.42). 4 (4%) masses sent to mammogram first and 2 (2%) masses sent to ultrasound first were not visualized. There was a significant difference in size between masses that were visualized under ultrasound versus those that were not (p = 0.01), when masses in both groups were assessed cumulatively. Conclusions: 98% of digital breast tomosynthesis screen-detected masses sent to ultrasound directly were adequately assessed without diagnostic mammography. Advances in knowledge: There is potential for avoiding a diagnostic mammogram for evaluation of majority of digital breast tomosynthesis screen-detected masses.